Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
July 01, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia receives approval from the European Commission (EC) for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO...
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
June 28, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority (obere kantonale...
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
June 25, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere...
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
June 21, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize...
Idorsia holds its Annual General Meeting of Shareholders
June 13, 2024 05:00 ET
|
Idorsia Pharmaceuticals Ltd
All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders...
New data with daridorexant to be presented at SLEEP 2024
June 03, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
New data with daridorexant to be presented at SLEEP 2024
June 03, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
May 23, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 23, 2024Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...